|
gptkbp:instanceOf
|
gptkb:drug
PARP inhibitor
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XX54
|
|
gptkbp:brand
|
Rubraca
|
|
gptkbp:CASNumber
|
283173-50-2
|
|
gptkbp:chemicalFormula
|
C19H18FN3O
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:developer
|
gptkb:Clovis_Oncology
|
|
gptkbp:eliminationHalfLife
|
17-19 hours
|
|
gptkbp:hasInChIKey
|
QJQYJQFISDJFHK-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
C1=CC(=CC=C1C2=NC(=NC(=N2)N3CCN(CC3)C4=CC=C(C=C4)F)O)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rucaparib
|
|
gptkbp:KEGGID
|
D10541
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits PARP enzymes
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
421.37 g/mol
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:Clovis_Oncology
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
9931957
CHEMBL1214097
DB12372
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
abdominal pain
constipation
fatigue
thrombocytopenia
decreased appetite
dysgeusia
|
|
gptkbp:target
|
gptkb:PARP1
gptkb:PARP2
gptkb:PARP3
|
|
gptkbp:UNII
|
D9F6R8K2J0
|
|
gptkbp:usedFor
|
gptkb:cancer
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:PARP1
|
|
gptkbp:bfsLayer
|
7
|